首页> 外文期刊>Artificial cells, nanomedicine, and biotechnology. >Development and characterization of ligand-appended liposomes for multiple drug therapy for pulmonary tuberculosis
【24h】

Development and characterization of ligand-appended liposomes for multiple drug therapy for pulmonary tuberculosis

机译:肺结核多药治疗中配体附加脂质体的开发与表征

获取原文
       

摘要

Tuberculosis (TB) remains one of the oldest and deadliest diseases in the current scenario. The intracellular organism Mycobacterium tuberculosis, which mainly resides in mononuclear phagocytes, is responsible for tuberculosis in humans. A few therapies are available for the treatment of tuberculosis but they have many hurdles. To overcome these hurdles, a combination of chemotherapeutic agent-loaded vesicular systems have been prepared to overcome tuberculosis. To investigate the role of novel drug delivery systems for the treatment of pulmonary tuberculosis, ligand appended liposomals have been developed. In the present study, drug-loaded, ligand-appended liposomes and their DPI (Dry Powder Inhaler) forms have been prepared and characterized using various in vitro and in vivo parameters. The prepared ligand-appended liposomal formulation showed good entrapment efficiency, prolonged drug release, improved recovery of drugs from the target site, and proved to be more suitable for use as DPI, justifying their potential for improved drug delivery. Thus we tried our best by our project to reduce the national burden of tuberculosis, which is still a global health challenge.
机译:在当前情况下,结核病(TB)仍然是最古老和最致命的疾病之一。主要存在于单核吞噬细胞中的细胞内生物结核分枝杆菌负责人类的结核病。有几种疗法可用于治疗结核病,但它们有许多障碍。为了克服这些障碍,已经准备了加载化学治疗剂的囊泡系统的组合以克服结核病。为了研究新型药物递送系统在治疗肺结核中的作用,已经开发了配体附加脂质体。在本研究中,已使用各种体外和体内参数制备并表征了载药的配体附加脂质体及其DPI(干粉吸入器)形式。制备的配体附加脂质体制剂显示出良好的包封效率,延长的药物释放,改善了从靶部位的药物回收率,并被证明更适合用作DPI,证明了其改善药物递送的潜力。因此,我们通过我们的项目尽了最大的努力来减轻结核病的国家负担,这仍然是全球卫生的挑战。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号